DARVOCET, DARVON AND PROPOXYPHENE PRODUCTS LIABILITY LITIGATION MDL 2226 TRANSFER ORDER

On August 16, 2011 the United States Judicial Panel on Multidistrict Litigation ordered that all pending federal cases involving injuries or deaths alleged to have been caused by the use of Darvocet, Darvon or generic Propoxyphene would be consolidated in MDL 2226. The Court accepted the defendants first choice of the Eastern District of Kentucky as site of the MDL. Read more »

Transvaginal Mesh

The use of transvaginal mesh for the treatment of stress urinary incontinence (SUI) and transvaginal repair of pelvic organ prolapse (POP) has been linked to serious complications including vaginal mesh erosion (also called exposure, extrusion or protrusion), pain (including painful sexual intercourse known as dyspareunia), infection, urinary problems, bleeding, and organ perforation.

Darvon/Darvocet

On November 19, 2010 Xanodyne Pharmaceuticals Inc. agreed to recall Darvon and Darvocet from the US market at the request of the Food & Drug Administration after studies showed adverse side effects.

FDA and European Regulators Severely Restrict Access To Avandia

in

In an almost unprecedented joint announcement, the FDA and European regulators announced that access to Avandia, a medication to treat diabetes marketed by GlaxoSmithKline, will be severely restricted. Read more »

DePuy Hip Replacement Recall

DePuy Orthopaedics is voluntarily recalling its ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System. This recall means additional testing and treatment may be necessary to ensure the hip is functioning well. In some cases, patients may need additional surgery. Call our DePuy Hip Implant lawyers for a free DePuy Hip Implant claim evaluation, (877) 917-5250

Drugsettlement.com member firm to commence first federal Paxil birth defect trial.

DrugSettlement.com, LLC, reports that one of its member firms, Nix & McIntyre, LLP, has been ordered by Judge Claire V. Eagan of the United States District Court for the Northern District of Oklahoma, to commence the first federal Paxil Birth Defect trial on October 19, 2009. The case has been profiled in a television news story by News9 in Oklahoma City, Oklahoma. Continue ⇒